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Gestational diabetes complicates up to 17% of all 
pregnancies and is a strong risk factor for gesta-
tional hypertensive disorders.1,2 In pregnant women 
with pregestational diabetes, hyperglycemia causes 
a proinflammatory environment and cytokine 
derangements, which act on the endothelium, and lead 
to placental vascular changes, whereas insulin may have 
a direct toxic effect on the placenta.3,4 Also, pregnancies 
complicated by obesity or gestational diabetes show 
dysregulation of metabolic, vascular, and inflammatory 
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BACKGROUND
Gestational diabetes mellitus is associated with increased risks of gesta-
tional hypertension and preeclampsia. We hypothesized that high ma-
ternal glucose concentrations in early pregnancy are associated with 
adverse placental adaptations and subsequently altered uteroplacental 
hemodynamics during pregnancy, predisposing to an increased risk of 
gestational hypertensive disorders.
METHODS
In a population-based prospective cohort study from early pregnancy 
onwards, among 6,078 pregnant women, maternal early-pregnancy 
non-fasting glucose concentrations were measured. Mid and late preg-
nancy uterine and umbilical artery resistance indices were assessed by 
Doppler ultrasound. Maternal blood pressure was measured in early, 
mid, and late pregnancy and the occurrence of gestational hyperten-
sive disorders was assessed using hospital registries.
RESULTS
Maternal early-pregnancy glucose concentrations were not as-
sociated with mid or late pregnancy placental hemodynamic 
markers. A  1  mmol/l increase in maternal early-pregnancy glucose 
concentrations was associated with 0.71 mm Hg (95% confidence in-
terval 0.22–1.22) and 0.48 mm Hg (95% confidence interval 0.10–0.86) 
higher systolic and diastolic blood pressure in early pregnancy, respec-
tively, but not with blood pressure in later pregnancy. Also, maternal 
glucose concentrations were not associated with the risks of gesta-
tional hypertension or preeclampsia.
CONCLUSIONS
Maternal early-pregnancy non-fasting glucose concentrations within 
the normal range are associated with blood pressure in early preg-
nancy, but do not seem to affect placental hemodynamics and the risks 
of gestational hypertensive disorders.
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pathways.5,6 This dysregulation is characterized by 
increased circulating concentrations of inflamma-
tory molecules and placental overexpression of genes 
encoding for inflammatory mediators.5,6 Studies have 
shown that hyperglycemia during pregnancy is asso-
ciated with reduced invasiveness of the trophoblast, 
increased oxidative stress in the maternal and fetal mi-
lieu, disrupted vasculogenesis, and macroscopically and 
histologically altered placentae.4,7–11 Treatment of gesta-
tional diabetes has been shown to reduce the prevalence 
of preeclampsia.12 It is not known yet to what extent 
early-pregnancy non-fasting glucose concentrations may 
influence early placental adaptations, blood pressure, and 
predispose women to gestational hypertensive disorders.
We hypothesized that high maternal glucose concentrations 
in early pregnancy are associated with adverse placental 
adaptations and subsequently altered uteroplacental hemo-
dynamics during pregnancy, predisposing to an increased 
risk of gestational hypertensive disorders. We examined in a 
low-risk, multiethnic, population-based prospective cohort 
study among 6,078 pregnant women, the associations of ma-
ternal early-pregnancy non-fasting glucose concentrations 
with placental flow measures, blood pressure throughout 
pregnancy, and gestational hypertensive disorders.
METHODS
Study design
This study was embedded in the Generation R Study, a 
population-based prospective cohort study from early preg-
nancy onwards in Rotterdam, The Netherlands. All pregnant 
woman and their children who were living within the city of 
Rotterdam at the time of birth were eligible to participate.13 
The study has been approved by the local Medical Ethical 
Committee (MEC 198.782/2001/31). Written consent 
was obtained from all participating women. All pregnant 
women were enrolled between 2001 and 2005. Response 
rate at birth was 61%.14 In total, 8,879 women were enrolled 
during pregnancy. For the current study, 6,869 women were 
eligible as they enrolled before 18 weeks of gestational age 
and had singleton livebirths. Women with no data on ma-
ternal early-pregnancy glucose metabolism or with all out-
come measures missing were excluded (n  =  763). Women 
with pregestational diabetes (n = 21) and women with un-
reliable glucose concentrations (<1 mmol/l) were excluded 
(n = 7). The population for analysis comprised 6,078 preg-
nant women (Figure  1). All measurements in pregnancy 
were performed by trained research assistants who were part 
of the study team.
Excluded n=763 due to no data on early-
pregnancy maternal glucose metabolism
available. Excluded n=21 due to 
pregestational diabetes. Excluded n=7 due to 
glucose measurements < 1mmol/l.
Total population for analysis n=6,078
Early pregnancy glucose measurement n=6,078
Early pregnancy insulin measurement n=6,063







Information on gestational hypertensive
disorders available n=5,460
Mothers enrolled before 18 weeks of gestational age,
with singleton live births, eligible for the current study
n=6,869
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Maternal glucose concentrations
Blood samples were collected once in early pregnancy at 13.2 
median weeks’ gestation (95% range 9.6;17.6), as described 
previously.15 After 30 minutes of fasting, venous blood samples 
were collected from pregnant women, by specifically trained 
research nurses who were part of the research team, and tem-
porally stored at room temperature for a maximum of 3 hours. 
We considered the 30 minutes fasting samples non-fasting 
samples. This time interval was chosen because of the design 
of our study, in which it was not possible to obtain fasting 
samples from all pregnant women. At least every 3 hours, blood 
samples were transported to a dedicated laboratory facility 
(Star-MDC, Rotterdam, The Netherlands), for further pro-
cessing and storage.16 Glucose (mmol/l) is an enzymatic quan-
tity and was measured with the c702 module on a Cobas 8000 
analyzer (Roche, Almere, The Netherlands). Insulin (pmol/l) 
was measured with electrochemiluminescence immunoassay 
on a Cobas e411 analyzer (Roche, Almere, The Netherlands). 
Quality control samples demonstrated intra- and interassay 
coefficients of variation of 1.30% and 2.50%, respectively. 
Information on pregestational diabetes mellitus was obtained 
from self-reported questionnaires and on gestational diabetes 
from medical records after delivery. Gestational diabetes was 
diagnosed by a community midwife or an obstetrician ac-
cording to Dutch midwifery and obstetric guidelines using 
the following criteria: either a random glucose concentrations 
>11.0 mmol/l, a fasting glucose ≥7.0 mmol/l, or a fasting glu-
cose between 6.1 and 6.9 mmol/l with a subsequent abnormal 
glucose tolerance test.17
Placenta hemodynamic characteristics
Ultrasound examinations were carried out in 2 dedi-
cated research centers in the city of Rotterdam in early (me-
dian 13.2 weeks gestational age, interquartile range (IQR) 
12.2;14.9), mid (median 20.4 weeks gestational age, IQR 
19.9;21.1), and late pregnancy (median 30.2 weeks gesta-
tional age, IQR 29.9;30.6). We established gestational age by 
using data from the first ultrasound examination.18 Uterine 
artery resistance index and umbilical artery pulsatility index 
were derived from flow velocity waveforms in mid and late 
pregnancy. Standard deviation scores for uterine artery re-
sistance index and umbilical artery pulsatility index were 
based on values from the whole study population and repre-
sent the equivalent of z-scores. Late pregnancy uterine artery 
notching was diagnosed if a notch was present uni- or bilat-
erally, as a result from increased blood flow resistance, which 
is a sign of placental insufficiency.19
Blood pressure and gestational hypertensive disorders
Blood pressure was measured at each pregnancy visit 
(median gestational age 13.2 weeks (IQR 12.2;14.9); 20.4 
weeks (IQR 19.9;21.1); and 30.2 weeks (IQR 29.9;30.6)) 
using an Omron 907 automated digital oscillometer sphyg-
momanometer (OMRON Healthcare Europe, Hoofddorp, 
The Netherlands).20 The mean value of 2 blood pressure 
readings over a 60-second interval was documented for each 
participant.21
Information about hypertensive disorders in pregnancy 
was obtained from medical records.14 The occurrence of hy-
pertension and related complications were cross-validated 
using hospital registries, and defined using criteria of the 
International Society for the Study of Hypertension in 
Pregnancy.22,23 Gestational hypertension was defined as 
de novo hypertension alone (an absolute blood pressure 
140/90 mm Hg or greater), appearing after 20 weeks gesta-
tional age. Preeclampsia was defined as de novo hypertension 
(blood pressure ≥140/90 mm Hg) after the 20th gestational 
week with concurrent proteinuria (0.3  g or greater in a 
24-hour urine specimen or 2+ or greater (1 g/l) on a voided 
specimen or 1+ or greater (0.3 g/l) on a catheterized spec-
imen). Any gestational hypertensive disorder was defined as 
either gestational hypertension or preeclampsia.
Covariates
Maternal height (cm) and weight (kg) were measured 
without shoes and heavy clothing at enrollment and body 
mass index (BMI, kg/m2) was calculated. Information about 
prepregnancy weight, ethnicity (European/non-European), 
and education (higher education yes/no) was obtained by 
questionnaire.14 Folic acid supplementation, categorized 
as use vs. no use, and parity, categorized as nulliparous or 
multiparous, were obtained at enrollment by question-
naire.24 Information about smoking was available from 
questionnaires, and was classified as “yes” if the woman 
smoked until pregnancy was known and if she continued to 
smoke throughout pregnancy.25
Statistical analyses
First, we conducted a nonresponse analysis to com-
pare characteristics of women with and without glu-
cose measurements available. Second, we assessed the 
associations of maternal early-pregnancy non-fasting glu-
cose concentrations continuously with mid and late preg-
nancy uterine artery and umbilical artery resistance indices 
and late pregnancy uterine artery notching, and with blood 
pressure in early, mid, and late pregnancy, using linear and 
logistic regression models. We also analyzed the longitudinal 
systolic and diastolic blood pressure patterns in women using 
unbalanced repeated measurement regression models.26 
These models take the correlation between repeated 
measurements of the same subject into account, and allow 
for incomplete outcome data. Using fractional polynomials 
of gestational age, the best-fitting models were constructed. 
For presentation purposes, we constructed tertiles of ma-
ternal glucose concentrations for these analyses. Third, we 
assessed the associations of maternal early-pregnancy non-
fasting glucose concentrations continuously with gestational 
hypertensive disorders (gestational hypertension and pree-
clampsia), using logistic regression models. For all analyses, 
we constructed different models to explore whether any as-
sociation was explained by maternal sociodemographic and 
lifestyle factors. The basic model was adjusted for gestational 
age at glucose measurement; the main model was addition-
ally adjusted for gestational age at assessment, maternal eth-
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supplement use; and the maternal BMI model was addi-
tionally adjusted for maternal prepregnancy BMI. Included 
covariates were based on previous studies, strong correlations 
with exposure and outcomes, and changes in effect estimates 
of >10%. We further tested but did not observe statistical 
interactions between maternal prepregnancy BMI and ma-
ternal early-pregnancy non-fasting glucose concentrations 
for the associations with uterine and umbilical artery resist-
ance indices and blood pressure. Statistical interaction terms 
were tested by including the term maternal prepregnancy 
BMI × maternal early-pregnancy non-fasting glucose 
concentrations in the regression model. We performed 3 sen-
sitivity analyses. First, analyses were repeated using maternal 
early-pregnancy non-fasting insulin concentrations. Second, 
to test whether the associations of maternal early-pregnancy 
non-fasting glucose concentrations with high blood pres-
sure we excluded women with gestational diabetes (n = 66). 
Third, to test whether a cutoff effect was present, we tested 
for differences in associations with blood pressure between 
women in quintiles of glucose concentrations, with the 
lowest quintile used as the reference group. We used mul-
tiple imputation for missing values of covariates according 
to Markov Chain Monte Carlo method.27 The percentage of 
missing data was <10%, except for smoking (15%) and folic 
acid supplement use (31.2%). Five imputed datasets were 
created and pooled for analyses. No significant differences 
in descriptive statistics were found between the original and 
imputed datasets. The repeated measurement analysis was 
performed using the Statistical Analysis System version 9.4 
(SAS Institute, Cary, NC), including the Proc Mixed module 
for unbalanced repeated measurements. All other analyses 
were performed using the Statistical Package of Social 
Sciences version 24.0 for Windows (IBM, Armonk, NY).
RESULTS
Population characteristics
Population characteristics are shown in Table  1. Mean 
maternal early-pregnancy glucose concentrations were 
4.4 mmol/l. In total, 64 (1.1%) women were diagnosed with 
gestational diabetes. Late pregnancy uterine artery notching 
occurred in 312 (10.2%) participants. Gestational hyper-
tension developed in 203 (3.8%) women and preeclampsia 
developed in 131 (2.4%) women. Nonresponse analyses 
showed that women without glucose measurements were 
more often parous, had a lower level of educational attain-
ment, used folic acid supplementation more often, were 
more often of non-European descent, and had a higher mid 
pregnancy and a lower late pregnancy uterine artery resist-
ance index (Supplementary Table S1 online). Histogram for 
maternal glucose concentrations given in Supplementary 
Figure S1 online.
Early-pregnancy glucose concentrations and placental 
hemodynamics
Maternal early-pregnancy glucose concentrations were 
not associated with mid and late pregnancy uterine artery 
Table 1. Characteristics of mothers (n = 6,078)
Characteristics
Maternal characteristics
 Age, mean (SD), years 29.8 (5.1)
 Height, mean (SD), cm 167.5 (7.4)
 Weight before pregnancy, mean (SD), 
kg
66.4 (12.7)
 Body mass index, median (IQR), kg/
m2
22.6 (20.7–25.4)
 Parity, no. nulliparous (%) 3,458 (57.4)
 Education, no. higher education (%) 2,538 (44.9)
 Race/ethnicity
  Dutch or European, no. (%) 3,558 (61.0)
  Surinamese, no. (%) 503 (8.6)
  Turkish, no. (%) 472 (8.1)
  Moroccan, no. (%) 352 (6.0)




  None, no. (%) 3,712 (72.2)
  Early-pregnancy only, no. (%) 452 (8.8)
  Continued, no. (%) 974 (19.0)
 Folic acid use, no. used (%) 2,943 (47.4)
 Pregestational diabetes mellitus,  
no. (%)
0 (0)
 Blood pressure, mean (SD), mm Hg
  Early pregnancy 115 (12.3)/68 (9.6)
  Mid pregnancy 116 (12.0)/67 (9.4)
  Late pregnancy 118 (12.0)/69 (9.4)
 Mid pregnancy uterine artery  
resistance index, mean (SD)
0.54 (0.09)
 Late pregnancy uterine artery 
resistance index, mean (SD)
0.49 (0.08)
 Late pregnancy uterine artery 
notching, no. (%)
312 (10.2)
 Glucose, mean (SD), mmol/l 4.4 (0.84)
 Insulin, median (IQR), pmol/l 115.1 (55.4–233.4)
 Gestational diabetes mellitus, no. (%) 64 (1.1)
 Gestational hypertension, no. (%) 203 (3.8)
 Preeclampsia, no. (%) 131 (2.4)
Birth characteristics
 Males, no. (%) 3,076 (50.6)
 Gestational age at delivery, median 
(IQR), weeks
40.1 (39.1–41.0)
 Preterm birth, no. (%) 310 (5.1)
 Birth weight, mean (SD), g 3,417 (564)
 Placenta weight, median (IQR), g 610 (530–720)
Values are observed data and represent means (SD), medians 
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resistance indices, umbilical artery pulsatility indices, and 
risk of late pregnancy uterine artery notching (Table 2).
Early-pregnancy glucose concentrations, blood pressure, 
and gestational hypertensive disorders
Associations of maternal early-pregnancy glucose 
concentrations with blood pressure in early, mid, and late 
pregnancy are shown in Table 3. A 1 mmol/l increase in ma-
ternal early-pregnancy glucose concentrations was associ-
ated with 0.71 mm Hg (95% confidence interval 0.22;1.22) 
and 0.48 mm Hg (95% confidence interval 0.10;0.86) higher 
systolic and diastolic blood pressure in early pregnancy, re-
spectively, but not with blood pressure in later pregnancy. 
Using repeated measurements analysis (Figure  2), we 
observed that tertiles of maternal early-pregnancy glucose 
concentrations were not associated with blood pressure over 
time (P value for interaction of early-pregnancy glucose 
concentrations with gestational age >0.05, Supplementary 
Table S5 online). Also, maternal early-pregnancy glucose 
concentrations were not associated with the risks of gesta-
tional hypertensive disorders (Table 4).
Sensitivity analyses
In mid pregnancy, higher insulin concentrations were as-
sociated with a higher umbilical artery pulsatility index in 
the basic and main model, but the association attenuated 
in the BMI model (Supplementary Table S2 online). In the 
BMI model, higher early-pregnancy insulin concentrations 
were associated with a higher early-pregnancy systolic blood 
pressure (Supplementary Table S3 online). We found sim-
ilar results to the main findings when we excluded women 
with gestational diabetes (data not shown). Finally, no 
differences in associations with blood pressure between 
women with non-fasting glucose concentrations in quintiles 
were observed (data not shown).
DISCUSSION
Our findings suggest that higher maternal early-
pregnancy non-fasting glucose concentrations are associ-
ated with higher blood pressure in early pregnancy, but no 
associations were present with blood pressure in mid or late 
pregnancy. Also, maternal early-pregnancy non-fasting glu-
cose concentrations were not associated with placental he-
modynamics or gestational hypertensive disorders.
Meaning of the current study and findings
Hyperglycemia during pregnancy is associated with 
miscarriage, fetal structural anomalies, fetal macrosomia, 
fetal demise, preterm birth, and gestational hyperten-
sive disorders.28,29 Limited evidence for early-pregnancy 
screening for diabetes in the general population exist, al-
though testing can be performed as early as the first prenatal 
visit if a high degree of suspicion of undiagnosed type 2 dia-
betes exists.28 Current clinical guidelines advise screening for 
pregestational diabetes among women with overweight and 
additional risk factors.28,30 In clinical practice, the diagnosis 
of gestational diabetes is usually made in second half of preg-
nancy. However, high glucose concentrations may already 
have contributed to risk of gestational hypertensive disorders 
and other adverse effects on maternal and fetal health before 
gestational diabetes and associated complications such as 
fetal macrosomia and polyhydramnios become apparent.29 
Optimization of glucose regulation in the case of gesta-
tional diabetes and pregestational diabetes leads to a strong 
reduction of risk of gestational hypertensive disorders.31 
Therefore, early pregnancy may be a critical period for ad-
verse effects of increased glucose concentrations on fetal 
and maternal pregnancy outcomes. Previously we reported 
associations of higher maternal early-pregnancy non-fasting 
glucose concentrations with decreased fetal growth rates in 
mid pregnancy and increased fetal growth rates from late 
Table 2. Associations of maternal early-pregnancy glucose concentrations with mid and late pregnancy placental flow measures (n = 4,236)
Maternal early-pregnancy glucose 
concentrations, mmol/l
Uterine artery Umbilical artery




Pulsatility index (95% 
confidence interval)
Mid pregnancy
 Basic model −0.00 (−0.02 to 0.02) Not available 0.03 (−0.01 to 0.07)
 Main model −0.00 (−0.05 to 0.04) Not available 0.03 (−0.01 to 0.07)
 BMI model −0.02 (−0.07 to 0.03) Not available 0.02 (−0.02 to 0.06)
Late pregnancy
 Basic model −0.00 (−0.03 to 0.02) 0.96 (0.84 to 1.09) −0.02 (−0.06 to 0.01)
 Main model −0.00 (−0.05 to 0.04) 0.95 (0.82 to 1.09) −0.02 (−0.06 to 0.02)
 BMI model −0.03 (−0.08 to 0.02) 0.92 (0.79 to 1.08) −0.02 (−0.07 to 0.02)
Values are SDSs (95% CI) from linear regression models, reflecting differences in measures of uterine and umbilical artery flow measures, 
and OR (95% CI) reflecting difference in risk of late pregnancy uterine artery notching, per 1 mmol/l increase in maternal early-pregnancy non-
fasting glucose concentrations. Estimates are from multiple imputed data. Basic model: adjusted for gestational age at glucose measurement. 
Main model: gestational age at glucose measurement, gestational age at ultrasound, maternal ethnicity, age, parity, educational level, smoking, 
and folic acid supplement use. BMI model: main model additionally adjusted for maternal prepregnancy BMI. Abbreviations: BMI, body mass 
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pregnancy onwards, and an increased risk of delivering a 
large-for-gestational-age infant.15 Early placenta develop-
ment may play an important role in these associations. Next 
to its adverse effects on fetal growth, inadequate placental 
development may play an important role in the development 
of gestational hypertensive disorders.
Early pregnancy is a critical period for optimal placenta 
development. In this period, trophoblast invasion and spiral 
artery remodeling takes place to ensure adequate blood flow 
to the placenta, leading to larger vessels with lower resist-
ance and increased end-diastolic flow.32 Normally, in early 
pregnancy, cardiac output increases, peripheral vascular re-
sistance is reduced, and blood pressure decreases until mid 
pregnancy, returning to baseline at term.32 If these processes 
are inadequate, increased blood pressure, abnormal uterine 
artery Dopplers with higher resistance indices and notching 
may be observed, and gestational hypertension or pree-
clampsia may develop. Previous studies have shown that 
women with prediabetes defined as HbA1c of 5.7–6.4% in 
early pregnancy represent a high-risk group for develop-
ment of gestational hypertensive disorders.33,34 It is unclear 
how early-pregnancy glucose concentrations across the full 
range influence placental flow measures, blood pressure, and 
gestational hypertensive disorders. We hypothesized that 
higher early-pregnancy non-fasting glucose concentrations 
negatively influence placental flow measures, blood pres-
sure, and risk of gestational hypertensive disorders.
Previous studies report associations of glucose 
concentrations with placental flow measures.35,36 In a study 
among 231 pregnant women with polycystic ovarian syn-
drome, early pregnancy and, more strongly, mid pregnancy 
fasting glucose concentrations, were positively associated 
with an increased mid-pregnancy uterine artery pulsatility 
index.35 A  retrospective study among 155 pregestational 
diabetic women suggested a positive correlation between 
concentrations of HbA1c and increased vascular resistance 
in the uterine and umbilical arteries, suggesting that hyper-
glycemia may influence uterine and placental vessel endo-
thelial function.36 In the current study in a low-risk healthy 
population, we did not observe associations of maternal 
early-pregnancy glucose concentrations with placental 
flow measures. The difference in results may be explained 
by our low-risk, nondiabetic population. Also, glucose 
concentrations in early pregnancy may not influence pla-
cental flow measures measured later in pregnancy.
Diabetes and hypertension often occur simultaneously 
and show a substantial overlap in disease etiology and risk 
factors, such as genetics, obesity, insulin resistance, and in-
flammation.37–39 Due to prolonged exposure to effects of 
hyperglycemia, we expected to find stronger associations of 
early-pregnancy glucose concentrations with blood pressure 
throughout pregnancy. In the current study, we observed 
associations of maternal early-pregnancy non-fasting glu-
cose concentrations with early-pregnancy blood pressure, 
but not later in pregnancy. Possibly, this may be due to the 
fact that the time between the exposure and the outcome is 
large, and as the effect estimates are already small and within 
the normal range in early pregnancy, the effect of early-
pregnancy glucose concentrations on blood pressure in mid 
or late pregnancy may not be detectable, or no association 
may present at all. Possibly, a more pronounced effect on 
cardiovascular outcomes may be observed in the presence 
of sustained elevated glucose concentrations. It has been 
shown that gestational diabetes leads to a strongly increased 
risk of gestational hypertensive disorders.1,2 Simultaneously, 
associations with gestational hypertensive disorders have 
Table 3. Associations of maternal early-pregnancy glucose concentrations with early, mid, and late pregnancy blood pressure (n = 5,265)
Maternal early-pregnancy glucose  
concentrations, mmol/l
Systolic blood pressure, mm Hg 
(95% confidence interval)
Diastolic blood pressure, mm Hg 
(95% confidence interval)
Early pregnancy
 Basic model 0.37 (−0.08 to 0.81) 0.40 (0.06 to 0.75)*
 Main model 0.47 (0.03 to 0.92)* 0.40 (0.06 to 0.75)*
 BMI model 0.71 (0.22 to 1.22)* 0.48 (0.10 to 0.86)*
Mid pregnancy
 Basic model 0.13 (−0.30 to 0.48) −0.13 (−0.44 to 0.18)
 Main model 0.19 (−0.21 to 0.59) −0.12 (−0.43 to 0.20)
 BMI model 0.36 (−0.09 to 0.80) −0.02 (−0.37 to 0.33)
Late pregnancy
 Basic model 0.21 (−0.18 to 0.61) 0.19 (−0.12 to 0.50)
 Main model 0.25 (−0.15 to 0.65) 0.18 (−0.13 to 0.49)
 BMI model 0.36 (−0.08 to 0.80) 0.24 (−0.10 to 0.59)
Values are mm Hg (95% CI) from linear regression models, reflecting differences in systolic and diastolic blood pressure, per 1 mmol/l in-
crease in maternal early-pregnancy non-fasting glucose concentrations. Estimates are from multiple imputed data. Basic model: adjusted for 
gestational age at glucose measurement. Main model: gestational age at glucose measurement, gestational age at blood pressure measure-
ment, maternal ethnicity, age, parity, educational concentrations, smoking, and folic acid supplement use. BMI model: main model additionally 
adjusted for maternal prepregnancy BMI. Abbreviations: BMI, body mass index; CI, confidence interval.
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middle tertile lowest tertile (ref) highest tertile
Figure 2. Longitudinal associations between tertiles of early-pregnancy glucose concentrations and blood pressure (n = 6,078). Blood pressure patterns in dif-
ferent maternal early-pregnancy glucose tertiles. (a) Systolic and (b) diastolic blood pressure in different maternal early-pregnancy glucose tertiles (n = 6,078). 
Results reflect the change in mm Hg in mothers with early-pregnancy glucose concentrations in the second (4.0–4.6 mmol/l) and third (4.6–10.3 mmol/l) 
tertiles, compared with those with glucose levels in the first tertile (0.3–4.0 mmol/l). (a) Systolic blood pressure = β0 + β1 × glucose tertile + β2 × gestational age 
+ β3 × gestational age−2 + β4 × glucose tertile × gestational age. (b) Diastolic blood pressure = β0 + β1 × glucose tertile + β2 × gestational age + β3 × gestational 
age0.5 + β4 × glucose tertile × gestational age. The models were adjusted for gestational age at intake. The interaction term of maternal early-pregnancy glucose 
tertile with gestational age in weeks was not significant. Similarly, when glucose was used continuously in the models, no significant interaction of maternal 
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not been found in women diagnosed with prediabetes in 
early pregnancy although these women are at increased 
risk of development of gestational diabetes.34,40 A previous 
prospective study among 4,589 healthy nulliparous women 
showed that even within the normal range, the plasma glu-
cose level 1 hour after 50-g oral glucose challenge was pos-
itively correlated with the likelihood of preeclampsia.41 As 
parity is a strong risk factor for preeclampsia, the baseline 
risk of gestational hypertensive disorders among this nullip-
arous population may be higher. In the current study, we did 
not find associations of early-pregnancy non-fasting glucose 
concentrations with risk of preeclampsia. This difference 
might be explained by differences in baseline risk and in glu-
cose measurements. Future studies, using early-pregnancy 
fasting glucose concentrations or glucose concentrations 
obtained after a standardized oral glucose challenge, are 
needed to confirm if early-pregnancy glucose concentrations 
are indeed associated with preeclampsia in a low-risk popu-
lation. We did not observe associations of maternal early-
pregnancy glucose concentrations across the full range, with 
gestational hypertensive disorders.
Findings from our study do not support strong effects 
of non-fasting glucose concentrations in early preg-
nancy within the normal range on the risks of gesta-
tional hypertensive disorders. In clinical practice, testing 
for pregestational diabetes is only recommended among 
high-risk populations.28,30,42 As pregnancy physiologically 
influences the glucose metabolism, future studies focused on 
prepregnancy glucose concentrations may shed an impor-
tant light on the effects of glucose concentrations on blood 
pressure, placental flow measures, and risk of gestational hy-
pertensive disorders.
Strengths and limitations
We had a prospective data collection from early preg-
nancy onwards and a large low-risk sample of 6,078 women 
with detailed glucose measurements, blood pressure, pla-
cental flow measures, and information on gestational hy-
pertensive disorders available. The response rate at baseline 
was 61%. The nonresponse at baseline might have led to 
selection of a healthier population. We had a population 
with a relatively low BMI, a low mean non-fasting glucose 
concentration, and the sample contained a small number of 
cases of gestational diabetes, indicating selection toward a 
nondiabetic population and might affect the generalizability 
of our findings to higher-risk populations in which stronger 
associations are expected. Blood sample collection was 
performed in a non-fasting state at different time points in 
the day. The minimum fasting time until blood sample col-
lection was 30 minutes, due to the design of the study. The 
samples were therefore considered as non-fasting blood 
samples. Since glucose and insulin concentrations are sen-
sitive toward carbohydrate intake and vary during the day, 
this may have led to non-differential misclassification and 
an underestimation of the observed effect estimates. We had 
no information available on oral glucose tolerance testing 
in pregnancy. Although we included many covariates, there 
still might be some residual confounding, as in any obser-
vational study. Further studies are needed to replicate our 
findings using more detailed maternal glucose metabolism 
measurements, including fasting glucose concentrations 
and detailed postprandial glucose measurements among 
higher-risk populations.
Maternal early-pregnancy non-fasting glucose 
concentrations across the full range are associated with 
blood pressure in early pregnancy, but not later in preg-
nancy. Also, maternal early-pregnancy non-fasting glucose 
concentrations within the normal range are not associated 
with placental flow measures and gestational hypertensive 
disorders.
SUPPLEMENTARY MATERIAL
Supplementary data are available at American Journal of 
Hypertension online.
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Table 4. Associations of maternal early-pregnancy glucose concentrations with the risks of gestational hypertensive disorders (n = 5,459)
Maternal early-pregnancy  
glucose concentrations, mmol/l
Gestational hypertension  
(95% confidence interval), n = 203
Preeclampsia  
(95% confidence interval), n = 131
Any gestational hypertensive disorder  
(95% confidence interval), n = 334
Basic model 1.01 (0.86 to 1.20) 0.98 (0.81 to 1.17) 0.95 (0.83 to 1.09)
Main model 1.02 (0.86 to 1.20) 0.87 (0.70 to 1.09) 0.96 (0.84 to 1.10)
BMI model 0.98 (0.82 to 1.18) 0.88 (0.69 to 1.11) 0.94 (0.81 to 1.09)
Values are ORs (95% CI) from logistic regression models, reflecting differences in risk of gestational hypertensive disorders, per 1 mmol/l 
increase in maternal early-pregnancy non-fasting glucose concentrations. Estimates are from multiple imputed data. Basic model: adjusted for 
gestational age at glucose measurement. Main model: gestational age at glucose measurement, maternal ethnicity, age, parity, educational 
level, smoking, and folic acid supplement use. BMI model: main model additionally adjusted for maternal prepregnancy BMI. Abbreviations: BMI, 
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